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Objective: The aim of this study was to explore the potential effects of diet-induced weight loss on
molecular biomarkers of colorectal cancer risk in serum and colorectal tissue.
Methods: This single-arm exploratory study included 20 adults with BMI 30 kg/m2 completing an 8-
week, complete, low-energy liquid diet. Pre- and postintervention anthropometric measurements, fasting
blood draws, and endoscopic examinations to procure colorectal biopsies were performed. Fasting insu-
lin, glucose, insulinlike growth factor 1 (IGF-1), C-reactive protein (CRP), and blood lipids were measured
in serum, and tissue markers of apoptosis (M30), colonocyte proliferation (Ki-67), and insulin signaling
(phospho-mTOR) were assessed using immunohistochemical staining.
Results: Participants achieved substantial weight loss (mean513.56%). Mean concentrations of insulin, glu-
cose, and cholesterol were significantly reduced (P< 0.05), but IGF-1 and CRP were not. Colorectal tissue
expression of Ki-67 was significantly reduced (preintervention mean score5 7, postintervention mean score5
3.9, mean % change243.8; P5 0.027). There were no significant changes in M30 or phospho-mTOR.
Conclusions: Weight loss in individuals with obesity was associated with improvements in insulin sensi-
tivity and blood lipid profiles and a significant reduction in tissue Ki-67 expression. This is one of the first
studies to demonstrate potential cancer-relevant changes in colorectal tissue following weight loss
achieved through diet.
Obesity (2017) 25, S95–S101. doi:10.1002/oby.21984
Introduction
Colorectal cancer (CRC) is the fourth most commonly diagnosed
malignancy in the United Kingdom, with 41,266 new cases diag-
nosed in 2014 and 15,903 deaths (1). Risk of CRC is increased sig-
nificantly in individuals with obesity (BMI 30 kg/m2) (2). With
more than a quarter of adults in the United Kingdom now classified
as having obesity (3), this is a potentially growing source of CRC
cases (4). Consequently, it is important to establish whether weight
loss can mitigate development of this malignancy.
Bariatric surgery, which leads to significant weight loss in individuals
with obesity, has been associated with a reduction in CRC (5,6),
though not all studies have reported reductions in risk (7-9). However,
there are no comparable data for dietary weight loss programs (10).
Weight loss achieved by nonsurgical methods is often poorly main-
tained in the long term, so investigation of the effects of interventions
based on diet-induced weight loss on cancer outcomes is difficult and
requires very large cohorts with long follow-up periods (11). An alter-
native approach is to investigate the effects of weight loss on molecu-
lar pathways and biomarkers that have been implicated in CRC devel-
opment. Weight loss achieved through low-energy (800 calories per
day) meal replacement diets offers an ideal paradigm for such investi-
gations because the weight loss achieved is typically rapid and sub-
stantial when adherence is good (12).
There is increasing consensus that the insulin/insulinlike growth fac-
tor 1 (IGF-1) axis and related inflammatory pathways play a
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significant role in the obesity-CRC link (13-17). Animal models of
CRC have shown significant modifications in these pathways fol-
lowing calorie restriction (18). In humans, intentional weight loss
and bariatric surgery yield favorable changes in circulating concen-
trations of insulin and inflammatory factors, such as C-reactive pro-
tein (CRP), though changes in IGF-1 are less consistent (19,20).
However, few studies have directly assessed the effect of weight
reduction on colorectal tissue.
A study in which 10 women with obesity achieved 10% weight loss
following a meal replacement diet found reductions in circulating
and rectal tissue concentrations of two markers of inflammation:
tumour necrosis factor alpha (TNF-a) and interleukin 8 (IL-8) (21).
Several randomized controlled trials of physical activity have also
demonstrated significant effects of exercise on both serum markers
and colon expression of proliferative markers and apoptotic factors
(22-24). Furthermore, a recent study found changes in Ki-67 (an
established marker of cell proliferation that has been identified as
potentially useful biomarker of cancer risk (25,26)) in colon tissue
following a change in diet, but the study did not measure weight
changes (25). These findings suggest that interventions that modify
energy balance can yield significant molecular changes at the colo-
rectal tissue level and add support to a potential antitumorigenic
effect of weight loss in the colorectum. The current analysis is a
small, single-arm study that aims to build on this research by explor-
ing the potential effects of diet-induced weight loss on serum
markers for CRC and changes in colorectal tissue expression of
markers of cell proliferation, apoptosis, and insulin signaling. The
findings from this study will inform the design of future larger
randomized controlled trials on weight loss and changes in CRC
biomarkers.
Methods
This was a single-arm exploratory study to explore the potential
effects of diet-induced weight loss on molecular biomarkers of CRC
risk in serum and colorectal tissue.
Participants
Twenty individuals with obesity (BMI 0 kg/m2) were recruited via
advertisements placed around University College London. Partici-
pants were recruited between July 2013 and July 2014. Participants
were required to be fluent in English, nonsmokers, and aged
between 18 and 60 years. Exclusion criteria included a history of
major depression, history of cardiovascular disease, pregnancy, tak-
ing medication prescribed by a general practitioner over the past
month (oral contraceptives were allowed), diabetes, or other diseases
(liver, kidney, heart, lung, blood, or skin). Potential participants
were also excluded if they had previously had intestinal surgery, a
history of malabsorption, or regularly used drugs with anti-
inflammatory or hypoglycaemic properties, as these would interfere
with the assessment of insulin-related parameters. Finally, individu-
als with a previous diagnosis of cancer were excluded, as this could
affect measured biomarkers.
Weight loss intervention
After an initial consultation and assessment with an obesity-
specialist physician, participants followed an 8-week liquid weight-
loss diet program (810 calories per day) based on formula diet
products (Cambridge Weight Plan, Northants, UK). Previous stud-
ies have shown this to be a safe and effective dietary method for
weight loss (27-29). The program was delivered by trained
researchers under the supervision of a registered dietician and
obesity-specialist clinician. Support and advice on behavior change
techniques were offered on a weekly basis in the form of face-to-
face contact. Each session lasted between 30 minutes and an hour.
Participants were requested to maintain their preintervention physi-
cal activity levels for the duration of the 8-week intervention. At
the end of the 8 weeks, 4 weeks of additional support were pro-
vided to help participants with meal reintroduction and weight loss
maintenance.
Study procedures
At baseline and at the 8-week follow-up point (i.e., on completion
of the weight-loss diet), a research nurse measured height, weight,
and waist circumference for each participant. Two 20-ml fasting
blood samples were taken for assessment of serum concentrations of
insulin, glucose, CRP, IGF-1, total cholesterol, high-density lipopro-
tein (HDL), and triglycerides.
Participants also underwent a flexible sigmoidoscopy at baseline and
follow-up to obtain colon and rectal biopsies. These procedures
were performed by an experienced Consultant Colorectal Surgeon at
the Colorectal Centre, University College London Hospital. For each
participant, and at each time point, biopsies (10-15) 1-mm thick
were obtained from different sections of the bowel that were acces-
sible during flexible sigmoidoscopy (sigmoid colon, rectum) and
were stored as formalin-fixed paraffin-embedded slides and as fresh
samples stored in RNALater.
Ethics
The study was approved by London–Harrow Research Ethics Com-
mittee (reference: 13/LO/0080) and was conducted in accordance
with the Helsinki Declaration of 1975 as revised in 1983. Written
informed consent was obtained from all participants before joining
the study. The study was registered on the ISRCTN registry as
ISRCTN35702367.
Laboratory methods
All serologic measurements were performed at Imperial College
NHS Trust Clinical Laboratories. Serum insulin, CRP, and IGF-1
were analyzed using enzyme-linked immunosorbent assays. Markers
of apoptosis (M30), colonocyte proliferation (Ki-67), and insulin sig-
naling pathway activation (phospho-mTOR) were assessed using
immunohistochemical staining in the laboratory of Professor Robert
Goldin, Imperial College, and Dr Naomi Guppy, University College
London. All staining was performed using the Leica Bond III auto-
mated immunostaining platform on the Leica Bond Polymer Refine
(Leica, DS9800) DAB polymer detection system. Ki-67 (mouse
monoclonal MIB-1, Dako, cat. no. M7240) was applied at a dilution
of 1/120 for 15 minutes at room temperature, following on-board
heat-induced epitope retrieval (HIER) using Leica Epitope Retrieval
2 (ER2, pH9 retrieval solution; Leica, AR9640) for 20 minutes.
M30 (mouse monoclonal M30 cytoDEATH, Roche, cat. no.
12 140 322 001) was applied at a dilution of 1/50 for 30 minutes at
room temperature, following on-board HIER using Leica Epitope
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Retrieval 1 (ER1, pH6 retrieval solution; Leica, AR9961) for 30
minutes. Phospho-mTOR (rabbit monoclonal 49F9, Cell Signaling
Technologies cat. no. 2976) was applied at a dilution of 1/50 for 20
minutes at room temperature, following on-board HIER using Leica
ER2 for 30 minutes.
Statistical analysis
This was an exploratory study, and so no formal sample size calcula-
tion was performed. Based on the previous study, which found signifi-
cant changes at the tissue level in 10 participants (21), we aimed for a
sample size of 10 to 20 to enable us to demonstrate feasibility and
potential effects of the weight loss intervention. The intervention
effects were evaluated by exploring the differences in the geometric
mean changes from baseline to 8 weeks by paired t tests and by gener-
alized estimating equation modification to linear regression models to
account for the longitudinal nature of the data. Serologic and tissue
expression data, if not normally distributed, was log transformed to
achieve normality prior to performing parametric analyses.
Results
Participants were mostly female (70%), aged 21 to 57 years, and of
white ethnicity (90%; Table 1). Participants had a mean baseline
BMI of 34.0 (32.2-36.0) and waist circumference of 102.5 (98.5-
106.7) (Table 2).
Participants achieved clinically important and beneficial anthropo-
metric outcomes (Table 2); weight loss was substantial, with a base-
line mean of 98.8 kg reduced to a follow-up mean of 85.4 kg (%
mean change, 213.6; P5 0.002). Mean BMI was also reduced from
34.0 kg/m2 to 29.4 kg/m2 (% mean change, 213.6; P5 0.0008).
Mean waist circumference was reduced by 11.9% (P5 0.0003).
We were unable to obtain blood samples pre- and post-weight loss
from three of the participants. For those participants for whom pre
and post blood samples were available (17/20; 85%), diet-induced
weight loss resulted in statistically significant mean reductions in
serum insulin (% mean change 244.5; P5 0.003), glucose (% mean
change 26.3; P5 0.01), HOMA-IR (% mean change 244.9;
P5 0.002), total cholesterol (% mean change 224.0; P5 0.0001),
and HDL (% mean change 219.0; P5 0.006). Mean concentrations
of IGF-1, CRP, and triglycerides were also reduced during the inter-
vention, but these changes did not meet statistical significance
(Table 2).
In linear mixed-model analyses, in addition to inducing significant
reductions in weight and other anthropometric parameters, the
weight loss intervention induced statistically significant reductions
in fasting insulin (b526.95; P5 0.002), glucose (b520.33;
P5 0.01), HOMA-IR (b521.81; P5 0.002), total cholesterol
(b521.17; P< 0.001), HDL (b520.27; P< 0.001), and triglycer-
ides (b520.15; P< 0.001) (Table 3).
Tissue analyses indicated an increase in apoptosis, as assessed by
M30, during the intervention (preintervention mean H-score5 8.4,
postintervention mean H-score5 52.2, mean % change, 521.0); but
the change did not attain statistical significance (P5 0.09). On the
other hand, concentrations of Ki-67, a proliferation marker, were
significantly reduced over the intervention period (preintervention
mean5 7.0; postintervention mean, 3.9; mean % change, 243.8%;
P5 0.027; Figure 1). We did not observe any changes in tissue con-
centrations of phospho-mTOR during the intervention.
Discussion
Previous studies have demonstrated changes in serum biomarkers
for CRC risk following weight loss (19,20), but few have explored
changes at the tissue level. In this exploratory study, weight loss
was associated with significant improvements in insulin sensitivity
and blood lipid profiles as well as a significant reduction in Ki-67
expression in colorectal tissue. The results of this analysis provide
preliminary evidence for weight-related molecular changes in the
colorectum following intentional weight loss achieved through a
low-energy meal replacement diet.
Combined with the previous study, in which a 10% diet-induced
weight loss led to reductions in circulating and rectal tissue concen-
trations of inflammatory markers in 10 women (21), these findings
lend support for a potential antitumorigenic effect of weight loss
among individuals with obesity. Ki-67 is an established marker of
cell proliferation and has been identified as a potentially useful bio-
marker of cancer risk (25,26). The evidence for the use of prolifera-
tion biomarkers in humans is based on the known increase in pro-
portion of epithelial cells engaged in DNA synthesis in premalignant
conditions of the colorectum, as well as the observed expansion of
the proliferative zone, causing a shift of the proliferating cells from
the base to the surface of the colonic crypt. It is currently unknown
at what point reductions in Ki-67 can be considered clinically mean-
ingful. However, the reduction in Ki-67 expression in colorectal tis-
sue observed in our study, alongside reductions in circulating insu-
lin, adds support for the hypothesis that changes in the insulin
signaling pathway may be an important mechanism through which
diet-induced weight loss influences cell proliferation in the colorec-
tum, and ultimately CRC risk. Studies with larger samples are
needed to confirm these findings and to explore whether changes in
circulating insulin mediate the association between weight loss and
reduced Ki-67.
TABLE 1 Baseline characteristics
n %









Highest level of education
Vocational qualification/A-level 6 (30%)
Degree or higher 13 (65%)
Other 1 (5%)
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In our study, we did not observe a significant change in circulating
concentrations of IGF-1 following weight loss. Despite experimental
and observational evidence supporting a role for IGF-1 signaling in
CRC development (13-15), our study did not provide evidence that
weight loss in individuals with obesity reduces circulating concen-
trations of IGF-1. This is in line with cohort studies and other inter-
vention studies that have demonstrated weak and inconsistent associ-
ations between intentional weight loss and changes in IGF-1,
leading some to conclude that changes in IGF-1 may not be a major
pathway through which weight changes modify cancer risk (19). We
did observe an increase in the apoptotic marker, M30, following the
intervention, although the change did not attain statistical signifi-
cance, which may be a consequence of the limited sample size.
Because a hallmark of cancer development is suppressed apoptosis,
a nominal increase in apoptosis observed during the intervention
supports a potential antitumorigenic effect of weight loss.
While our study suggests weight loss could mitigate the risk of CRC
for individuals with obesity, some studies of bariatric surgery have
demonstrated an increased risk of CRC following weight loss
achieved through surgical means (7-9). Some have suggested that






mean (95% CI) P value
Weight (kg) 98.78 (92.59 to 105.39) 85.39 (79.82 to 91.34) 213.56
(213.73 to 13.39)
0.002
Waist circumference (cm) 102.54 (98.54 to 106.71) 90.32 (85.62 to 95.27) 211.93
(212.09 to 211.76)
0.0003
BMI (kg/m2) 34.01 (32.15 to 36.0) 29.40 (27.63 to 31.28) 213.56
(213.73 to 213.39)
0.0008
Waist to hip ratio 0.86 (0.82 to 0.90) 0.82 (0.78 to 0.85) 25.10
(25.26 to 24.93)
0.08
Insulin (mIU/L) 11.55 (8.44 to 15.82) 6.42 (5.15 to 8.00) 244.47
(244.66 to 244.29)
0.003
Glucose (mmol/L) 5.24 (4.96 to 5.54) 4.91 (4.63 to 5.21) 26.31
(26.48 to 26.14)
0.01
HOMA-IR 1.51 (1.11 to 2.06) 0.83 (0.67 to 1.04) 244.85
(245.03 to 244.66)
0.002
IGF-1 (nmol/L) 22.27 (19.93 to 24.88) 20.69 (17.86 to 23.98) 27.08
(27.26 to 26.91)
0.40
CRP (mg/L) 2.43 (1.54 to 3.85) 1.94 (1.25 to 2.99) 220.52
(220.72 to 220.32)
0.44
Total cholesterol (mmol/L) 4.88 (4.47 to 5.32) 3.70 (3.35 to 4.10) 224.01
(224.18 to 223.84)
0.0001
HDL (mmol/L) 1.41 (1.27 to 1.56) 1.14 (1.02 to 1.27) 219.0
(219.18 to 218.84)
0.006
Triglycerides (mmol/L) 0.93 (0.78 to 1.10) 0.81 (0.72 to 0.90) 213.0
(213.15 to 212.81)
0.17
Ki-67 7.0 (6.0 to 8.0) 3.9 (2.3 to 7.0) 243.8
(244.16 to 243.51)
0.027
M30 8.4 (2.9 to 24.2) 52.2 (5.9 to 459.5) 521.0
(2520.14 to 2522.18)
0.09
phospho-mTOR 208.0 (148.6 to 291.0) 219.1 (172.5 to 278.5) 5.38
(25.09 to 25.66)
0.77
TABLE 3 Linear mixed modeling analysis of the effect of the
intervention on anthropometric parameters and serum
biomarker levels
B-coefficient (95% CI) P
Weight 213.34 (214.72 to 212.0) <0.001
BMI 24.57 (24.96 to 24.17) <0.001
Waist circumference 212.0 (213.7 to 210.31) <0.001
Hip circumference 28.53 (210.41 to 26.65) <0.001
Waist to hip ratio 20.04 (20.06 to 20.02) <0.001
Glucose 20.33 (20.56 to 20.10) 0.01
Insulin 26.95 (29.2 to 23.04) 0.002
HOMA-IR 21.81 (23.21 to 20.75) 0.002
IGF-1 21.22 (24.0 to 21.66) 0.38
CRP 20.92 (22.01 to 20.17) 0.09
Total cholesterol 21.17 (21.41 to 20.94) <0.001
HDL 20.27 (20.39 to 20.02) <0.001
Triglycerides 20.15 (20.29 to 20.65) <0.001
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Figure 1 (A) Ki-67 immunohistochemical staining in colorectal tissue. (B) M30 staining.
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the increased risk of CRC following surgery may be a consequence
of changes to the microbiome (8), and there is increasing interest in
the role of gut microflora in obesity and cancer (30). A recent study
found changes in components of the microbiome hypothesized
to affect cancer risk following a change in dietary fat and fiber
alongside changes in Ki-67 in colon tissue (21). It is possible that
microbiome changes may be driving the observed reductions in cell
proliferation rather than changes in the insulin signaling pathway.
However, the microbiome is also known to be associated with host
insulin sensitivity (26), and it is therefore challenging to tease apart
these related components. Future studies of the impact of weight
loss on CRC risk markers may consider evaluating changes in the
gut microbiome alongside other biomarkers of CRC risk.
The current study was exploratory, and therefore the sample size was
small. Although we observed effects of weight loss on serologic
markers of CRC risk and Ki-67, the confidence intervals were wide. It
will, therefore, be important to replicate our findings in studies with
larger samples. Our small sample also meant that we were unable to
explore gender differences in the observed serum and tissue changes.
Links between CRC and obesity are stronger for men than for women
(31); however, as with most weight loss studies (32), the majority of
our sample were female. Similarly, we were not able to explore differ-
ences by baseline metabolic profile. Our study did include individuals
with a “healthier obese” phenotype, i.e., individuals with BMI 30
kg/m2 but who did not exhibit metabolic abnormalities such as hyper-
insulinemia and who may not have the same risk of CRC as those indi-
viduals with a less healthy metabolic profile (29,30). Future studies
might explore associations between improvements in metabolic health
and subsequent changes in tissue markers for CRC risk.
Our sample was relatively healthy and so may not be representative
of the wider population with obesity that may also have other
comorbidities. Furthermore, our sample was relatively young, and
CRC is typically diagnosed in older age groups. However, there
have been recent increases in CRC diagnoses at younger ages, which
may be a consequence of lifestyle changes at the population level
(31,32). Therefore, our observation of changes in tissue in this
younger sample may be an important indicator that weight and
weight changes can influence the risk of CRC from an early age.
An additional limitation of this study was the lack of a control group.
Although a single-arm design is common in biomarker-intervention
studies, a control group would help to substantiate the indication that
the observed changes are a consequence of the observed weight loss.
Meal replacement products not only induce weight loss, but also alter
an individual’s diet (e.g., the nutritional balance). Teasing out the role
of dietary change versus weight change is a challenge, given these fac-
tors are somewhat inextricably linked. The previous study reporting
changes in Ki-67 following dietary change (25) did not report whether
there were also any changes in weight. Future studies might seek to
explore the impact of a meal replacement diet that does not reduce
energy intake, and should include measures of physical activity. Fur-
thermore, our intervention was short (8 weeks) and our participants
were either still in negative energy balance or had only just reached a
weight plateau. It could be important to consider whether these find-
ings would be maintained after a period of sustained weight loss and
what happens to the profile of these changes if weight is regained.
Dietary programs that typically achieve smaller amounts of weight
loss are the most widely used method of weight reduction (33,34),
and the latest obesity guidance (35,36) recommends that a loss of
just 3% of body weight may have health benefits. It will therefore
be important from a public health perspective to explore the changes
seen at the tissue level with smaller amounts of weight loss. Future
research should also seek to better understand the long-term impact
of weight loss on markers for CRC risk and to quantify the amount
and duration of weight loss required for sustained benefits to an
individual’s CRC risk, as well as the impact of any weight regain.
Although the current study was exploratory and in a small healthy
sample, it is one of the few studies to investigate this level of
weight loss achieved through nonsurgical means and its effects on
both serologic and colorectal tissue markers. Our findings suggest
that substantial intentional weight loss achieved through a low-
energy meal replacement diet is feasible in this “healthy” population
with obesity, has an impact on markers for CRC in serum, and
reduces cell proliferation in colon tissue. Replicating these findings
in larger samples and incorporating microbiome and other metabolic
data may help us to better understand the potential impact of weight
loss on risk of CRC for individuals with obesity and the mechanisms
underlying the obesity-CRC link.O
Acknowledgments
We would like to thank Dr. Anthony Leeds for his thoughtful input
into this study. We would also like to acknowledge the substantial
intellectual contribution by Professor Jane Wardle who sadly passed
away prior to publication and is very much missed by all of her
colleagues.
VC 2017 The Authors. Obesity published by Wiley Periodicals, Inc. on
behalf of The Obesity Society (TOS)
References
1. Cancer Research UK. Bowel cancer risk factors. http://www.cancerresearchuk.org/
health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer#heading-Three.
Accessed December 2015.
2. Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and
colorectal cancer: findings from 56 observational studies. Obes Rev 2010;11:19-30.
3. Health Survey for England 2011: health, social care, and lifestyles: summary of key
findings 2011. Health and Social Care Information Centre. 2012.
4. Jarvis D, Mitchell JS, Law PJ, et al. Mendelian randomisation analysis strongly
implicates adiposity with risk of developing colorectal cancer. Br J Cancer 2016;
115:266-272.
5. Adams TD, Hunt SC. Cancer and obesity: effect of bariatric surgery. World J Surg
2009;33:2028-2033.
6. Afshar S, Kelly SB, Seymour K, Lara J, Woodcock S, Mathers JC. The effects of
bariatric surgery on colorectal cancer risk: systematic review and meta-analysis.
Obes Surg 2014;24:1793-1799.
7. Ostlund MP, Lu Y, Lagergren J. Risk of obesity-related cancer after obesity surgery
in a population-based cohort study. Ann Surg 2010;252:972-976.
8. Derogar M, Hull MA, Kant P, Ostlund M, Lu Y, Lagergren J. Increased risk of
colorectal cancer after obesity surgery. Ann Surg 2013;258:983-988.
9. Sainsbury A, Goodlad RA, Perry SL, Pollard SG, Robins GG, Hull MA. Increased
colorectal epithelial cell proliferation and crypt fission associated with obesity and
roux-en-Y gastric bypass. Cancer Epidemiol Biomarkers Prev 2008;17:1401-1410.
10. Karahalios A, English DR, Simpson JA. Weight change and risk of colorectal
cancer: a systematic review and meta-analysis. Am J Epidemiol 2015;181:832-845.
11. Ballard-Barbash R, Hunsberger S, Alciati MH, et al. Physical activity, weight
control, and breast cancer risk and survival: clinical trial rationale and design
considerations. J Natl Cancer Inst 2009;101:630-643.
12. Leslie WS, Taylor R, Harris L, Lean MEJ. Weight losses with low-energy formula
diets in obese patients with and without type 2 diabetes: systematic review and
meta-analysis. Int J Obes (Lond) 2017;41:96-101.
13. Kiunga GA, Raju J, Sabljic N, Bajaj G, Good CK, Bird RP. Elevated insulin
receptor protein expression in experimentally induced colonic tumors. Cancer Lett
2004;211:145-153.
Obesity Weight Loss and CRC Biomarkers Beeken et al.
S100 Obesity | VOLUME 25 | SUPPLEMENT 2 | NOVEMBER 2017 www.obesityjournal.org
14. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin,
body size, and incident colorectal cancer. J Natl Cancer Inst 1999;91:1147-
1154.
15. Limburg PJ, Stolzenberg-Solomon RZ, Vierkant RA, et al. Insulin, glucose, insulin
resistance, and incident colorectal cancer in male smokers. Clin Gastroenterol
Hepatol 2006;4:1514-1521.
16. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk
in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding
protein-3. J Natl Cancer Inst 1999;91:620-625.
17. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth
factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl
Cancer Inst 2000;92:1592-1600.
18. Mai V, Colbert LH, Berrigan D, et al. Calorie restriction and diet composition
modulate spontaneous intestinal tumorigenesis in Apc(Min) mice through different
mechanisms. Cancer Res 2003;63:1752-1755.
19. Byers T, Sedjo RL. Does intentional weight loss reduce cancer risk? Diabetes Obes
Metab 2011;13:1063-1072.
20. Ashrafian H, Ahmed K, Rowland SP, et al. Metabolic surgery and cancer:
protective effects of bariatric procedures. Cancer 2011;117:1788-1799.
21. Pendyala S, Neff LM, Suarez-Farinas M, Holt PR. Diet-induced weight loss reduces
colorectal inflammation: implications for colorectal carcinogenesis. Am J Clin Nutr
2011;93:234-242.
22. Friedenreich CM, Neilson HK, Woolcott CG, et al. Changes in insulin resistance
indicators, IGFs, and adipokines in a year-long trial of aerobic exercise in
postmenopausal women. Endocr Relat Cancer 2011;18:357-369.
23. McTiernan A, Yasui Y, Sorensen B, et al. Effect of a 12-month exercise
intervention on patterns of cellular proliferation in colonic crypts: a randomized
controlled trial. Cancer Epidemiol Biomarkers Prev 2006;15:1588-1597.
24. Campbell KL, McTiernan A, Li SS, et al. Effect of a 12-month exercise intervention
on the apoptotic regulating proteins Bax and Bcl-2 in colon crypts: a randomized
controlled trial. Cancer Epidemiol Biomarkers Prev 2007;16:1767-1774.
25. O’Keefe SJ, Li JV, Lahti L, et al. Fat, fibre and cancer risk in African Americans
and rural Africans. Nat Commun 2015;6:6342. doi:10.1038/ncomms7342
26. Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the
diagnosis of cancer (review). Mol Med Rep 2015;11:1566-1572.
27. Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic
review and meta-analysis of weight-loss clinical trials with a minimum 1-year
follow-up. J Am Diet Assoc 2007;107:1755-1767.
28. Riecke BF, Christensen R, Christensen P, et al. Comparing two low-energy diets for
the treatment of knee osteoarthritis symptoms in obese patients: a pragmatic
randomized clinical trial. Osteoarthritis Cartilage 2010;18:746-754.
29. Tsai AG, Wadden TA. The evolution of very-low-calorie diets: an update and meta-
analysis. Obesity (Silver Spring) 2006;14:1283-1293.
30. Ohtani N. Microbiome and cancer. Semin Immunopathol 2015;37:65-72.
31. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and
incidence of cancer: a systematic review and meta-analysis of prospective
observational studies. Lancet 2008;371:569-578.
32. Pagoto SL, Schneider KL, Oleski JL, Luciani JM, Bodenlos JS, Whited MC. Male
inclusion in randomized controlled trials of lifestyle weight loss interventions.
Obesity (Silver Spring) 2012;20:1234-1239.
33. Yoong SL, Carey ML, Sanson-Fisher RW, D’Este C. A cross-sectional study
assessing the self-reported weight loss strategies used by adult Australian general
practice patients. BMC Fam Pract 2012;13:48. doi:10.1186/1471-2296-13-48
34. Madigan CD, Daley AJ, Kabir E, Aveyard P, Brown W. Cluster analysis of
behavioural weight management strategies and associations with weight change in
young women: a longitudinal analysis. Int J Obes (Lond) 2015;39:1601-1606.
35. Stegenga H, Haines A, Jones K, Wilding J. Identification, assessment, and
management of overweight and obesity: summary of updated NICE guidance. BMJ
2014;349:g6608. doi:10.1136/bmj.g6608
36. Jensen MD, Ryan DH, Donato KA, et al. Expert Panel Report: Guidelines (2013)
for the management of overweight and obesity in adults. Obesity (Silver Spring)
2014;22(suppl 2):S41-S410.
Obesity and Cancer Supplement Obesity
ENERGETICS AND CANCER
www.obesityjournal.org Obesity | VOLUME 25 | SUPPLEMENT 2 | NOVEMBER 2017 S101
